Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Why a Genomic Test Like the Oncotype DX Genomic Prostate Score® (GPS) test?

Clinical features alone may not show the whole picture

Biopsy alone does not always accurately differentiate candidates for active surveillance.

GG = Grade group; GS = Gleason Score; RP = radical prostatectomy

~1 in 4 patients with a GS 6 at biopsy had more aggressive disease (GS >=7) at surgery1

~1 in 5 patients with a GS 7 at biopsy had less aggressive disease (GS 6) at surgery1

Biopsies often do not accurately categorize risk because of tumor heterogeneity, multifocality, and undersampling in prostate cancer.2



More accurate measures of tumor aggressiveness lead to more treatment decisions.

GENETIC VS GENOMIC

Genetic tests screen for inherited risk factors or spontaneously arising mutations. They can help identify the risk of getting cancer or how a tumor may respond to certain therapies.3

Genomic tests examine gene expression levels within a sample of tumor tissue. They provide information about the tumor's biology and aggressiveness.3

What elevates the GPS™ test above other tests?

Tissue-based genomic assays vary in their validation data to predict long-term and short-term outcomes. They also differ in the ability of their results to help guide the active surveillance decision in low-risk and favorable intermediate-risk patients.

The only assay designed for critical treatment decisions in clinically low-risk, early-stage prostate cancer

Bring together biology, validation, and endpoint insights to soar above the competition:


  Decipher® Prostate Biopsy Prolaris®
Genes selected based on performance in biopsy setting  1,4 Genes selected to perform in radical prostatectomy specimens5 Genes selected based on correlation with cell cycle progression pathway6
Optimized for small prostate biopsy tissue samples 5 ng of RNA7 25-100 ng of RNA8 25-500 ng of RNA9
Predicts Adverse Pathology in AS candidate patient cohorts*

7 studies
N1=395**
N4=402**
N10=114**
N11=134
N12=749
N13=432
N14=215
Total N=2441

2 studies
N15=266
N16=647
Total N=913

Predicts pT3a+/Extra Prostatic Extension  12

*Studies performed in biopsy samples from clinically low risk and/or AS-candidate patient cohorts
**GPS Validation Studies

Choose the GPS test to connect key insights for quick and actionable treatment decisions.


Order the GPS test now